Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of 1 of the following: * Ovarian epithelial cancer * Fallopian tube cancer * Primary peritoneal carcinoma * Recurrent or persistent disease * Must have received 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease * Initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation therapy, or extended therapy administered after a surgical or nonsurgical assessment * Patients who have not received prior paclitaxel-based chemotherapy must receive a second regimen that includes paclitaxel or docetaxel * Platinum-resistant or refractory disease, defined by 1 of the following: * Treatment-free interval of \< 6 months after completion of platinum-based therapy * Persistent disease at completion of primary platinum-based therapy * Progressive disease during platinum-based therapy * Paclitaxel-resistant disease, defined as having had a treatment-free interval \< 6 months or shown disease progression during paclitaxel-based therapy * Patients who have not received prior paclitaxel-based chemotherapy must receive a second regimen that includes paclitaxel or docetaxel * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan * Must have ≥ 1 target lesion that can be used to assess response * Tumors within a previously irradiated field are designated as non-target lesions unless progression is documented or biopsy confirms persistence ≥ 90 days after completion of radiotherapy * Not a candidate for a higher priority GOG protocol * GOG performance status 0-2 * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9.0 g/dL * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Bilirubin normal * SGOT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * No active infection requiring antibiotics * No sensory or motor neuropathy \> grade 1 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * PT INR ≤ 1.5 or in-range INR 2-3 (if patient is on a stable dose of therapeutic warfarin) * PTT \< 1.2 times control * No concurrent serious medical or psychiatric illness, including serious active infection * No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) * No uncompensated congestive heart failure or symptomatic coronary artery disease * No myocardial infarction within the past 6 months * No active bleeding * No other invasive malignancies within the past 5 years except for nonmelanoma skin cancer * No history of allergic reactions attributed to chemical or biological composition to paclitaxel or other study agents * No concurrent amifostine or other protective reagents * Recovered from prior surgery, radiotherapy, or chemotherapy * No prior paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) * No prior cancer treatment that would preclude study therapy * No additional prior cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens * One additional prior noncytotoxic regimen (i.e., monoclonal antibodies, cytokines, or small molecule inhibitors of signal transduction) for management of recurrent or persistent disease allowed * At least 1 week since prior hormonal therapy directed at the malignant tumor * Concurrent hormone replacement therapy allowed * At least 3 weeks since other prior therapy directed at the malignant tumor, including biologic therapy, immunologic agents, or radiotherapy * More than 5 years since prior chemotherapy for any other portion of the abdominal cavity or pelvis, unless for treatment of ovarian, primary peritoneal, or fallopian tube cancer * Prior adjuvant chemotherapy for localized breast cancer allowed provided it was completed \> 3 years ago and patient remains free of recurrent or metastatic disease * More than 5 years since prior radiotherapy to any other portion of the abdominal cavity or pelvis, unless for treatment of ovarian, primary peritoneal, or fallopian tube cancer * Prior radiotherapy for localized breast cancer, cancer of the head and neck, or skin cancer allowed provided it was completed \> 3 years ago and patient remains free of recurrent or metastatic disease * No prior radiotherapy to \> 25% of marrow-bearing areas